Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684786 | 0.91 | KMT2A (0.37) | PLAUALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL13640075 | 0.90 | ALDH1A1 (0.33) | ALDH1A1TSHRKMT2AMEN1CCR5 | |
| SCHEMBL10189567 | 0.85 | ALDH1A1 (0.38) | PLAUALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL2143658 | 0.85 | ALDH1A1 (0.38) | PLAUALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL12825104 | 0.85 | ALDH1A1 (0.38) | PLAUALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL12239062 | 0.84 | PLAU (0.38) | PLAUALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL12239199 | 0.83 | PLAU (0.35) | PLAU | |
| SCHEMBL2143674 | 0.82 | ALDH1A1 (0.35) | PLAUALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL12239065 | 0.82 | PLAU (0.39) | PLAU | |
| SCHEMBL12238996 | 0.82 | PLAU (0.36) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | PLAU 4443/4885ALDH1A1 1317/4885TSHR 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.